The Research 'Stakeholder Insight: HIV Therapy Dynamics' Shows That the Top 5 Most Popular Regimens Selected By Physicians Account for Only 13% of Patients in Salvage Therapy
Posted on: Friday, 16 November 2007, 09:00 CST
Research and Markets (http://www.researchandmarkets.com/reports/c74552) has announced the addition of Stakeholder Insight: HIV Therapy Dynamics to their offering.
Introduction
Despite several developments in efforts to tackle the spread of HIV, the total number of people living with HIV has continued to increase across the 6MM. However, significant advances in HIV disease understanding, treatment and management mean that the outlook for patients has considerably improved.
Scope
- Current epidemiology of HIV in the six major markets, including prevalence, diagnosis rates and patients split by line of therapy and drug regimens.
- A detailed examination of the patient numbers on each line of therapy, their drug regimens and preferences.
- Evaluation of the factors determining prescription choices and their respective level of influence.
- An assessment of the perception of new products in development and of key unmet needs within HIV.
Highlights
In the US and M5EU the total number of people living with HIV is continuing to increase. According to the physician survey, the total number of diagnosed patients across the 6MM is 1.1 million, of which 18% are treatment-naïve and approx. 800.000 are currently receiving therapy.
The complexity of HAART begins to increase as patients progress to later stages of therapy, with regimens consisting of up to 6 different drugs. Treatment also becomes much more individualized: This research shows that the top 5 most popular regimens selected by physicians account for only 13% of patients in salvage therapy.
Prescription choice is largely driven by patient and product-specific qualities, but the influence of these issues varies according to line of therapy. Efficacy and resistance profile exert an increasing influence as the patient becomes more treatment-experienced.
Reasons to Purchase
- Identify the key factors underlying prescription choice for treatment of HIV.
- Examine the current unmet needs in the HIV market and identify opportunities for new product development.
- Enhance your commercial positioning through an improved understanding of the HIV market dynamics.
Content Outline:
About Our Healthcare
About The Infectious Diseases And Respiratory Pharmaceutical Analysis Team
Chapter 1 Executive Summary
Chapter 2 Introduction And Scope
Chapter 3 Country Treatment Trees
Chapter 4 Epidemiology And Patient Segmentation
Chapter 5 Diagnosis And Treatment Rates
Chapter 6 Treatment Options And Trends
Chapter 7 Prescribing Influences And Brand Assessment
Chapter 8 Improving Treatment Outcomes And New Product Development
Bibliography
Appendix A
Appendix B
List Of Tables
List of Figures
Products Mentioned:
- Awareness
- GS-9137 (elvitegravir)
- MK-0518 (raltegravir)
- Selzentry/Celsentri (maraviroc)
- TMC125 and TMC278
- Vicriviroc
For more information visit http://www.researchandmarkets.com/reports/c74552.
Source: Datamonitor
Source: Business Wire
Related Articles
- Local Neurosurgeon Co-Authors National Treatment Guidelines for Brain Tumor Patients
- Computer System Improves Pain Therapy For Cancer Patients
- AHF Blasts GlaxoSmithKline Print Ads That Promote Fear of HIV Treatment
- Sucampo Pharmaceuticals Initiates Phase 2 Trial of Cobiprostone for the Treatment of Portal Hypertension in Patients With Liver Cirrhosis
- New Non-Invasive Treatment Option for Lung Cancer Patients Offered By CyberKnife Center of Miami
- Somaxon Pharmaceuticals to Announce Results of Phase 3 Clinical Trial of SILENOR(TM) for the Treatment of Insomnia in Elderly Patients and Host Conference Call
- Resonance Liked to HIV Treatment
- Complete Care Medical, Inc., Announces Agreement Between Diabetes Gold, Inc. And Patient Advocates for Prescription Drugs, Inc.
- Complete Care Medical, Inc., Announces Accord Between Carepharm LLC and Patient Advocates for Prescription Drugs, Inc.; Agreement Expected to Immediately Increase Carepharm's Mail Order Pharmacy Business
- New Study Results Find That Patients Treated With Boosted INVIRASE, A Potent Anti-HIV Treatment, Showed No Significant Resistance to Protease Inhibitors
 |
 |
User Comments (0)
RSS Feeds